All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

The IGNYTE-ESO study is looking at a new type of cancer treatment called T-cell therapy. It is designed for adults with specific rare cancers called synovial sarcoma or myxoid/round cell liposarcoma. Your immune system uses T cells to fight off illness, but cancer cells can sometimes hide from them. In this Phase II study, doctors collect some of your immune cells and update them in a laboratory. This change helps the cells spot a specific protein found on these tumours. Once the cells are ready, they are given back to you through a drip. The main goals of the study are to find out whether this treatment shrinks tumours, how long any benefits last, and what side effects may occur. This helps doctors learn if the treatment is safe and effective for people with these specific types of cancer.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
USWM Ct LLC
Enrolment target
21
Start
17 Jun 2024

What is this study about?

This clinical trial is researching a new treatment for two rare types of cancer known as synovial sarcoma and myxoid/round cell liposarcoma. Both are soft-tissue sarcomas, which are cancers that develop in muscles, fat, or joints. When standard treatments like chemotherapy or surgery are no longer working well, doctors need new, targeted options to help keep the cancer under control.

The treatment being tested is a type of immunotherapy known as T-cell therapy. T cells are a natural part of your immune system that fight infections. In this study, doctors take some of your T cells and give them a temporary 'upgrade' in a specialised laboratory. They add a new sensor to the cells so they can recognise a protein called NY-ESO-1, which often sits on the surface of these specific sarcoma cells.

Once updated, these living cells are put back into your bloodstream to search for and attack the tumour cells. This trial is important because it helps scientists find out if this personalised approach can shrink tumours and stop cancer from growing, while carefully checking how safe the treatment is for patients.

Key takeaways

  • The IGNYTE-ESO study tests a modified immune cell treatment for rare soft-tissue cancers.
  • It uses your own T cells, updated in a laboratory to hunt down tumour cells.
  • Open to adults aged 18 and older with synovial sarcoma or myxoid/round cell liposarcoma.
  • Requires specific markers (HLA-A2 and NY-ESO-1 or LAGE-1a) found through testing.
  • Involves hospital visits, an infusion of cells, regular scans, and ongoing follow-up.
  • Taking part is completely voluntary, and you can withdraw at any time.

Who may be eligible?

This study is open to adults aged 18 and over who have been diagnosed with either synovial sarcoma or myxoid/round cell liposarcoma. Both men and women can take part.

To be suitable, your body and your tumour must have specific biological features. Doctors will test your tissue to see if you have a common tissue type known as HLA-A2, and they will check your tumour for the NY-ESO-1 or LAGE-1a proteins. The treatment can only work if these exact targets are present.

You will also need to have a general health check. The study team will look at your blood tests and check that your heart, lungs, liver, and kidneys are working well enough for you to receive the treatment safely.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am 18 years of age or older.
  2. I have been diagnosed with synovial sarcoma or myxoid/round cell liposarcoma.
  3. I am willing to have blood and tumour tests to check for specific markers.
  4. I am well enough to attend hospital visits, have scans, and stay overnight if needed.
  5. I am open to trying an experimental cell-based immunotherapy.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves several stages over a number of months, followed by long-term check-ups. First, you will attend hospital for a procedure called apheresis, where a machine collects some of your white blood cells through a drip. You then have a resting period of a few weeks while your cells are sent to a laboratory to be updated.

Before you receive your new cells, you may need a short course of mild chemotherapy to prepare your body. You will then stay in hospital for the cell infusion and be closely watched for a few days to manage any immediate reactions. After leaving hospital, you will have regular visits for blood tests, physical checks, and scans (such as CT or MRI scans) to see how the tumour is responding. You will continue to be monitored for a few years to track your long-term health.

Potential risks and benefits

The main hope of this study is that the modified cells will find and shrink your tumours, helping you live longer without the cancer growing. However, there is no guarantee that the treatment will work for everyone. The treatment can also cause side effects, such as fever, fatigue, or low blood cell counts, and sometimes the immune system can react too strongly, requiring hospital care. Taking part is completely voluntary. You can choose to leave the study at any time, and your regular NHS medical care will continue as normal.

Locations (4)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain
  • —
    Unverified
    Netherlands
  • —
    Unverified
    France
  • —
    Unverified
    Italy

Common questions

What is T-cell therapy?

It is a type of treatment that uses your own immune cells. Doctors collect them, train them in a lab to recognise cancer, and return them to your body to fight the tumour.

How do doctors know if my tumour has the right protein?

The study team will test a small sample of your tumour (a biopsy) and take a blood sample to check your tissue type before you join.

Will I have to stay overnight in hospital?

Yes. You will usually need to stay in hospital for several days after receiving your cells so the medical team can watch you closely and manage any side effects.

Can I leave the trial if I change my mind?

Yes, you can leave the study at any point without giving a reason. Your doctors will continue to look after you with standard treatments.

Does it cost anything to take part?

No, the study treatment and tests are provided without charge. You may also get help with travel costs to and from hospital visits.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Master Protocol to Assess the Safety and Antitumor Activity …" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.